{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-003658","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.392387+00:00","generated_at":"2026-06-27T05:00:20.840248+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"COMPASS Pathways reports FY2021 net loss $71.7M; positive phase IIb TRD results, FDA meeting in April","bullets":["Net loss for FY2021 was $71.7M ($1.79 loss per share), vs $60.3M in FY2020; Q4 net loss $25.7M.","Cash balance $273.2M at year-end 2021, up from $190.3M in 2020; well-capitalized for phase III.","Positive phase IIb trial of COMP360 psilocybin for TRD: rapid and sustained response at 25mg dose.","End-of-phase II meeting with FDA scheduled for late April 2022; phase III expected H2 2022.","New senior executives: Dr Guy Goodwin (CMO), Mike Falvey (CFO), Matt Owens (General Counsel)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-003658","json":"https://secwatch.observer/filing/0001628280-22-003658.json","markdown":"https://secwatch.observer/filing/0001628280-22-003658.md","text":"https://secwatch.observer/filing/0001628280-22-003658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000162828022003658/0001628280-22-003658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000162828022003658/cmps-20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:00:20.840248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}